Entries by Dan Zapata

La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2016 and Recent Corporate Progress

SAN DIEGO–(BUSINESS WIRE)– La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today reported financial results for the three and nine months ended September 30, 2016 and recent corporate progress. Recent Corporate Progress In […]

La Jolla Pharmaceutical Company Receives Positive Opinion from European Orphan Committee for LJPC-401

SAN DIEGO–(BUSINESS WIRE)– La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opinion recommending LJPC-401 (synthetic human […]

La Jolla Pharmaceutical Company Reports Positive Results from Phase 1 Study of LJPC-401

La Jolla Pharmaceutical Company Reports Positive Results from Phase 1 Study of LJPC-401 -Dose-dependent, Statistically Significant Reduction in Serum Iron Observed (p=0.008) -LJPC-401 Well Tolerated; No Dose-Limiting Toxicities at Any Dose Level -Conference Call at 9:00 AM Eastern Time on Thursday, September 8, 2016 SAN DIEGO–(BUSINESS WIRE)– La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company […]

La Jolla Pharmaceutical Company Announces Agreement with European Medicines Agency on Pivotal Study of LJPC-401

La Jolla Pharmaceutical Company Announces Agreement with European Medicines Agency on Pivotal Study of LJPC-401 -Conference Call at 9:00 AM Eastern Time on Thursday, September 8, 2016 SAN DIEGO–(BUSINESS WIRE)– La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in […]

La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2016

SAN DIEGO–(BUSINESS WIRE)– La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today reported financial results for the three and six months ended June 30, 2016. Results of Operations As of June 30, 2016, […]

La Jolla Pharmaceutical Company to Provide Corporate Overview at the Jefferies 2016 Global Healthcare Conference

SAN DIEGO–(BUSINESS WIRE)– La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that George F. Tidmarsh, M.D., Ph.D., President and Chief Executive Officer of La Jolla, will provide a corporate overview at […]

La Jolla Pharmaceutical Company Announces First Quarter 2016 Financial Results and Recent Corporate Progress

SAN DIEGO–(BUSINESS WIRE)– La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today reported first quarter 2016 financial results and highlighted recent corporate progress. Recent Corporate Progress La Jolla’s ATHOS (Angiotensin II for the […]

La Jolla Pharmaceutical Company to Provide Corporate Overview at the Cowen and Company 36th Annual Health Care Conference

SAN DIEGO–(BUSINESS WIRE)– La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the Company will provide a corporate overview at the Cowen and Company 36th Annual Health Care Conference taking place March 7–9 […]

La Jolla Pharmaceutical Company Announces Fourth Quarter and Full Year 2015 Financial Results and Highlights Corporate Progress

SAN DIEGO–(BUSINESS WIRE)–La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today reported fourth quarter and full year 2015 financial results and highlighted 2015 corporate progress. La Jolla Pharmaceutical Company Announces Fourth Quarter and […]

La Jolla Pharmaceutical Company to Provide Corporate Overview at the 2016 BIO CEO & Investor Conference

SAN DIEGO–(BUSINESS WIRE)– La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the Company will provide a corporate overview at the 2016 BIO CEO & Investor Conference taking place February 8–9 […]